Mayne Pharma Group Limited

ASX Code



Pharmaceuticals- Biotechnology & Life Sciences

Investor Centre





Mayne Pharma Group Limited (Mayne Pharma) is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma's roots can be traced to FH Faulding and Co, for many years one of the largest and most prominent public companies headquartered in South Australia. A technology driven company, Mayne Pharma has a significant product portfolio and pipeline, global reach through distribution partners in Australia, North America, Europe and Asia and two product development and manufacturing facilities based in Salisbury, Australia and Greenville, North Carolina, USA with expertise in formulating complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds. The business is supported by over 850 staff globally with more than 200 scientists employed.


MYX - UBS rates the stock as Neutral
MYX - UBS rates the stock as Neutral
Mayne Pharma Plots US Contraceptives Expansion
MYX - UBS rates the stock as Neutral